Gan & Lee Pharmaceuticals (603087.SH), founded in 1998, is a global biopharmaceutical company centered on independent innovation. Guided by its mission “Delivering high-quality medicines and services to improve lives worldwide,” the company maintains deep expertise in core endocrine and metabolic therapeutic areas while proactively expanding into frontier fields including oncology, autoimmune diseases, and gene and cell therapies. The company strives to become a global innovation leader in endocrine and metabolic therapeutics.

Gan & Lee was the first domestic company to achieve the industrialization of recombinant insulin analogs and has spearheaded transformations within China’s insulin industry. It offers a comprehensive portfolio spanning the full spectrum of long-acting, rapid-acting, and premixed insulin products and secured the largest total contracted volume among all winning bidders in the 2024 National Volume-Based Procurement exclusively for insulin.

Through a steadfast commitment to innovation-driven R&D, Gan & Lee has established advanced technology platforms covering peptides, PROTAC, oligonucleotide therapeutics, and antibodies, building end-to-end R&D capabilities from original innovation to industrialization. With integrated R&D centers and manufacturing facilities in Beijing and Linyi, Shandong, the company holds over 80 international registration certificates, with its products commercially available in more than 21 countries across Eurasia, the Asia-Pacific, Latin America, and Africa.